ω-conotoxins gvia, mviia and cvid sar and clinical potentialω-conotoxins gvia mviia cvid sar和临床潜力.pdfVIP

ω-conotoxins gvia, mviia and cvid sar and clinical potentialω-conotoxins gvia mviia cvid sar和临床潜力.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
ω-conotoxins gvia, mviia and cvid sar and clinical potentialω-conotoxins gvia mviia cvid sar和临床潜力

Mar. Drugs 2006, 4, 193-214 Marine Drugs ISSN 1660-3397 © 2006 by MDPI /marinedrugs Special Issue on “Marine Drugs and Ion Channels” Edited by Hugo Arias Review ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential Christina I. Schroeder and Richard J. Lewis* Institute for Molecular Bioscience, The University of Queensland, St Lucia, 4072, QLD, Australia E-mail: t.schroeder@.au (for Christina I. Schroeder) * To whom correspondence should be addressed. Tel: +61-7-3346 2984; Fax: +61-7-3346 2101. E-mail: r.lewis@.au Received: 16 February 2006 / Accepted: 28 February 2006 / Published: 6 April 2006 Abstract: Highly selective N-type voltage-gated calcium (Ca ) channel inhibitors from V cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω- conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain. Keywords: ω-conotoxin, Structure-Activity relationship, pain. Abbreviations: FDA, Food and Drug Administration; AChR, nicotinic ac

您可能关注的文档

文档评论(0)

118zhuanqian + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档